Circulating Biomarkers for Glioma: A Review. Issue 3 (13th January 2021)

• Record Type: Journal Article
• Authors: Jones, Jordan; Nguyen, Hong; Drummond, Katharine; Morokoff, Andrew
• Is Part Of: Neurosurgery. Volume 88:Issue 3(2021)
• Page Start: E221
• Page End: E230
• Publication Date: 2021-01-13
• Subjects: Glioma -- Glioblastoma -- Circulating biomarkers -- Liquid biopsy; Nervous system -- Surgery -- Periodicals; 617.48005
• DOI: 10.1093/neuros/nyaa540
• Languages: English
• ISSNs: 0148-396X

Abstract

Abstract: Accurate circulating biomarkers have potential clinical applications in population screening, tumor subclassification, monitoring tumor status, and the delivery of individualized treatments resulting from tumor genotyping. Recently, significant progress has been made within this field in several cancer types, but despite the many potential benefits, currently there is no validated circulating biomarker test for patients with glioma. A number of circulating factors have been examined, including circulating tumor cells, cell-free DNA, microRNA, exosomes, and proteins from both peripheral blood and cerebrospinal fluid with variable results. In the following article, we provide a narrative review of the current evidence pertaining to circulating biomarkers in patients with glioma, including discussion of the advantages and challenges encountered with the current methods used for discovery. Additionally, the potential clinical applications are described with reference to the literature.